Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
129.26
+1.51 (1.18%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Gilead Sciences Revenue
In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth. Gilead Sciences had revenue of $7.93B in the quarter ending December 31, 2025, with 4.70% growth.
Revenue (ttm)
$29.44B
Revenue Growth
+2.40%
P/S Ratio
5.45
Revenue / Employee
$1,731,941
Employees
17,000
Market Cap
160.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.44B | 689.00M | 2.40% |
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
GILD News
- 21 hours ago - Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
- 1 day ago - AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities - Business Wire
- 6 days ago - Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Business Wire
- 11 days ago - Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - Business Wire
- 14 days ago - PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access - Business Wire
- 15 days ago - Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing - Business Wire
- 18 days ago - AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
- 19 days ago - Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Business Wire